# Teriparatide for postmenopausal osteoporosis.

> PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15587764-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15587764-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15587764-teriparatide-v1.json
- Content SHA-256: `9058d139d8c967b812487ac0b39ff265a281b9da7596a4b5197e1651050d4a5d`

## Claims and source pins

### Headline

Teriparatide for postmenopausal osteoporosis. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

### Summary

PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

### Paragraph 1

PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

## Sources

<a id="source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956"></a>
- **Teriparatide for postmenopausal osteoporosis. · retained source version 1:2013-11-21:current:1a9eea2a3956c3f4159f4466e89b99a923eafe806e5cb9e81cf3a771768da3ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15587764/) (`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Teriparatide for postmenopausal osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15587764-teriparatide-v1.json SHA-256: 9058d139d8c967b812487ac0b39ff265a281b9da7596a4b5197e1651050d4a5d.